{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T21:39:20Z","timestamp":1788817160504,"version":"build-2803163510"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Tumor lysis syndrome (TLS) is a rare complication following treatment in prostate cancer patients. We present a 65-year-old man with history of castration-resistant prostate cancer who developed TLS following 2 sessions of <jats:sup>177<\/jats:sup>Lu-PSMA therapy. The patient presented with bulky axillary and mediastinal lymphadenopathies, an unusual site for prostate cancer metastasis. Although his PSA levels declined following treatment, he reported excessive weakness leading to immobility. Laboratory correlation showed markedly increased lactate dehydrogenase, from 413 to 543,000 U\/L, suggesting the occurrence of TLS. Although being considered a relatively safe treatment, <jats:sup>177<\/jats:sup>Lu-PSMA can sometime lead to life-threatening events, which is reviewed here.<\/jats:p>","DOI":"10.1097\/rlu.0000000000005445","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T14:00:09Z","timestamp":1728050409000},"page":"e617-e618","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Tumor Lysis Syndrome Following PSMA Radioligand Therapy"],"prefix":"10.1097","volume":"49","author":[{"given":"Pegah","family":"Sahafi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Hadi","family":"Samadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran","family":"Aryana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2973-2251","authenticated-orcid":false,"given":"Emran","family":"Askari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib1-20250621","first-page":"39","article-title":"Tumor lysis syndrome","year":"2014","journal-title":"Renal Disease in Cancer Patients"},{"key":"bib2-20250621","first-page":"273","article-title":"Tumor lysis syndrome","volume":"13","year":"1993","journal-title":"Semin Nephrol"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"752","DOI":"10.2967\/jnumed.118.217380","article-title":"Tumor lysis syndrome: a rare but serious complication of radioligand therapies","volume":"60","year":"2019","journal-title":"J Nucl Med"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.2967\/jnumed.120.258533","article-title":"Liver enzyme elevation after 177Lu-PSMA radioligand therapy for metastasized castration-resistant prostate cancer","volume":"62","year":"2021","journal-title":"J Nucl Med"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1158\/1078-0432.CCR-22-2875","article-title":"FDA approval summary: lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer","volume":"29","year":"2023","journal-title":"Clin Cancer Res"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.2967\/jnumed.123.265759","article-title":"The Tyr phenomenon: a hypocalcemic response in high-volume treatment responders to 177Lu-prostate-specific membrane antigen therapy","volume":"64","year":"2023","journal-title":"J Nucl Med"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.eururo.2022.05.025","article-title":"Extensive 177Lu-PSMA radioligand therapy can lead to radiation nephropathy with a renal thrombotic microangiopathy\u2013like picture","volume":"83","year":"2023","journal-title":"Eur Urol"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s00259-018-4222-x","article-title":"Outcome and safety of rechallenge [177 Lu] Lu-PSMA-617 in patients with metastatic prostate cancer","volume":"46","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005445","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:07:10Z","timestamp":1750532830000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":8,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005445","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]}}}